BCR-ABL1 Transcript ≤10% IS an Early Molecular Response Predictor of Treatment-Free Remission Eligibility in Chronic Myeloid Leukemia.
| Publicado en: | Clinical Lymphoma, Myeloma & Leukemia Vol. 26; no. 7; pp. 447 - 456 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Journal Article |
| Publicado: |
Elsevier B.V.
Jul2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=196096820&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 196096820 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 21522650 B54U jtl: Clinical Lymphoma, Myeloma & Leukemia issn: 21522650 maglogo: N pubinfo: dt: Jul2026 vid: 26 iid: 7 pid: 467 pub: Elsevier B.V. place: New York, New York artinfo: ui: 196096820 10.1016/j.clml.2026.04.007 196096820 ppf: 447 ppct: 9 formats: tig: atl: BCR-ABL1 Transcript ≤10% IS an Early Molecular Response Predictor of Treatment-Free Remission Eligibility in Chronic Myeloid Leukemia. aug: au: Rasekh, Eman O. Sherif, Menna M. Ibrahim, Nagwa Ibraheem, Dalia Ghareeb, Mohamed Elfishawi, Sally affil: Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|